EUCTR2006-001846-15-SE进行中（未招募）不适用
A placebo-controlled, randomised, double-blind, single dose proof of concept study of Kappaproct, in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degree
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients, =18 years of age.
- •2. Well established UC, of mild or moderate degree, defined as a Schroeder DAI score of 6-11.
- •3. GCS treatment resistant or dependent (=5mg per day of prednisolon or equivalent treatment for 4 weeks) or in cases of a known history of clinical steroid resistance not responding adequately to =5mg per day of prednisolon or equivalent treatment for =2 weeks.
- •4. Endoscopy score of =2.
- •5. At least one previous verified attack of UC within the last 3 years prior to randomization.
- •6. Current UC relapse with onset =12 months prior to randomization.
- •7. Current UC disease location should extend more than 10 cm from the anal verge but not beyond the left colonic flexure, as verified by an appropriate endoscopic method (rigid sigmoidoscopy/colonoscopy).
- •8. Visible blood in stools at least once within a week prior to randomization.
- •9. Infectious cause ruled out through negative stool culture.
- •10. If ongoing treatment with oral 5-ASA or SASP, the dose regimen must have been unchanged for at least 4 weeks prior to randomization and the therapy must have been initiatied at least 12 weeks prior to randomisation
- •11. Has given signed informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Remicade less than 8 weeks ago.
- •2. Previous colectomy with ileorectal anastomosis. Patients that have undergone subtotal colectomy or ileosigmoidal anastomosis are eligible for inclusion.
- •3. Impaired rectal compliance. Eligible patients must be expected to be able to hold at least 50 mL.
- •4. An active infection, i.e. fever (>38oC).
- •5. Anaemia (Hb<100g/L).
- •6. History or presence of a clinical significant cardiovascular, hepatic, renal, haematological, endocrine, neurological or psychiatric disease or immune compromised state.
- •7. History or presence of colonic dysplasia, including adenomas within 5 years prior to randomization.
- •8. History or presence of any malignancy.
- •9. Any surgical event within 2 weeks prior to Baseline.
- •10. Treated with ciclosporine A, FK 506 or a similar biologic agent one month prior to Baseline.
- •11. Treated with Non-Steriodal Anti-Inflammatory Drugs (NSAID)s within one week prior to Baseline.
- •12. Treated with antibiotics within one week prior to Baseline.
- •13. Concomitant participation in another clinical study. Received an investigational drug within 3 months prior to randomization.
- •14. During the study pregnant or nursing women and women of childbearing potential (i.e. female who is not surgically sterile or postmenopausal) not using reliable contraceptive methods (barrier protection, hormonal contraception, intra-uterine device or abstinence). The same applies to men i.e not using reliable contraceptive methods such as condom and spermicide.
- •15. Inability to understand instructions/written information.
研究者
相似试验
进行中（未招募）
不适用
Study to evaluate the effect on lung function and ECG when a combination of tiotropium plus olodaterol is administered to patients with COPD either from a single inhaler or each compound is administered after each other from two different inhalersMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Chronic Obstructive Pulmonary DiseaseEUCTR2013-002652-32-DEBoehringer Ingelheim Pharma GmbH & Co. KG58
已完成
不适用
A randomised, double-blind, placebo controlled, single and multiple dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NMD670 in male and female healthy subjects and patients with myasthenia gravis.1000381610029317Myasthenia GravisNL-OMON54930MD Pharma A/S79
已完成
1 期
Safety, blood levels and effects of AUT00201Phase I study in healthy volunteers of a treatment to improve/or normalize symptoms and deficits in patients with rare neurological disorders associated with reduced Kv3 channel functionISRCTN18263497Autifony Therapeutics (United Kingdom)57
进行中（未招募）
不适用
A trial to compare lomitapide at different doses with placebo with regards to safety, what the drug does, and where the drug goes, in Japanese and Caucasian volunteers who have higher then normal cholesterol levelsPersons with elevated low-density-lipoprotein - cholesterol levels (at least 110 mg/dL).MedDRA version: 14.1Level: LLTClassification code 10024055Term: LDL cholesterol increasedSystem Organ Class: 100000004848EUCTR2012-004220-37-GBAegerion Pharmaceuticals Inc
进行中（未招募）
1 期
A Phase IIb trial to examine the immune system response and safety of the FLU-v vaccine administered to healthy adultsInfluenza A and/or BMedDRA version: 19.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-001932-38-NLPepTcell Limited (trading as SEEK)175